Cytomegalovirus infection secondary prevention

Jump to navigation Jump to search

Cytomegalovirus infection Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cytomegalovirus infection from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Cytomegalovirus infection secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cytomegalovirus infection secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cytomegalovirus infection secondary prevention

CDC on Cytomegalovirus infection secondary prevention

Cytomegalovirus infection secondary prevention in the news

Blogs on Cytomegalovirus infection secondary prevention

Directions to Hospitals Treating Cytomegalovirus infection

Risk calculators and risk factors for Cytomegalovirus infection secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aravind Kuchkuntla, M.B.B.S[2]

Overview

Secondary prophylaxis of CMV infection includes preemptive treatment with antiviral agents in asymptomatic patients with positive blood PCR for CMV DNA.

Secondary Prevention

  • Preemptive treatment with antiviral agents in asymptomatic patients with positive blood PCR for CMV DNA.[1][2][3]

References

  1. Santos CA (2016). "Cytomegalovirus and Other β-Herpesviruses". Semin Nephrol. 36 (5): 351–361. doi:10.1016/j.semnephrol.2016.05.012. PMID 27772620.
  2. Potena L, Solidoro P, Patrucco F, Borgese L (2016). "Treatment and prevention of cytomegalovirus infection in heart and lung transplantation: an update". Expert Opin Pharmacother. 17 (12): 1611–22. doi:10.1080/14656566.2016.1199684. PMID 27340928.
  3. Kotton, C. N. (2013). "CMV: Prevention, Diagnosis and Therapy". American Journal of Transplantation. 13 (s3): 24–40. doi:10.1111/ajt.12006. ISSN 1600-6135.